株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ジカウィルス調査:感染症診断市場および人間用ワクチン市場に焦点を置いた、ジカ熱の急速な拡大の影響

The Zika Virus Report: Implications of the Rapid Spread of Zika with a Focus on the Infectious Disease Diagnostics Market and Human Vaccines Market

発行 Visiongain Ltd 商品コード 352539
出版日 ページ情報 英文 78 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.86円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
ジカウィルス調査:感染症診断市場および人間用ワクチン市場に焦点を置いた、ジカ熱の急速な拡大の影響 The Zika Virus Report: Implications of the Rapid Spread of Zika with a Focus on the Infectious Disease Diagnostics Market and Human Vaccines Market
出版日: 2016年02月15日 ページ情報: 英文 78 Pages
概要

当レポートは、ジカウィルス大流行の今後の方向性および拡大の影響について調査しており、感染症診断市場・人間用ワクチン市場の分析と予測、ジカウィルス診断・ワクチンパイプラインの分析、ジカウィルスの症状、伝染、歴史、および経済的・社会的影響などについて、まとめています。

第1章 レポート概要

第2章 ジカウィルス:イントロダクション

  • ジカウィルス
    • フラビウイルスの構造
    • ジカウィルスの複製機構
    • 伝染の形態
  • ジカウィルス大流行前の概要
  • ZIVDの症状
    • 小頭症

第3章 ジカウィルスの大流行 2015/2016年

  • 南北アメリカにおけるジカ熱の進行
  • ジカウィルス感染の危険性がある地域
    • ネッタイシマカの生息地域
    • ヒトスジシマカの生息地域
  • 封じ込め手段
    • 影響を受けた諸国の取り組み
    • 影響を受けていない諸国の取り組み
  • 基本再生産数 (繁殖率)
    • 関連ウィルスの基本再生産数

第4章 ジカウィルス感染の診断ツール

  • 感染症診断市場
  • 感染症診断市場の予測
  • ジカウィルス感染の診断
    • ジカウィルス疾患の診断向けラボ検査
    • 業務用・ポイントオブケア検査

第5章 ジカウィルスワクチン:パイプライン候補薬

  • 世界のワクチン市場
  • 世界のワクチン市場予測
  • 人間用ワクチンの主要メーカー
    • GlaxoSmithKline (GSK)
    • Merck & Co (MSD)
    • Sanofi
    • Pfizer
  • 現在入手可能なジカウィルス以外のワクチン
  • ジカウィルスワクチンのパイプライン
    • Bharat Biotech
    • Sanofi Pasteur
    • Inovio Pharmaceuticals
    • その他の企業

第6章 ジカウィルス大流行の経済・社会経済的影響

  • 影響を受けた諸国への影響の概要
  • 影響を受けた諸国におけるジカウィルスと妊娠
  • 観光と大きなイベント
  • ヘルスケアサービス・サポート
  • 将来の拡大の影響の予測

第7章 用語

図表リスト

目次
Product Code: PHA0089

What can be expected as the Zika outbreak progresses? Which areas are going to be the most affected? This visiongain report discusses the future direction of the Zika virus outbreak and the implications of its spread. It also discussed the infectious disease diagnostics market and the global human vaccines market, both of which are forecast to 2026. The pipeline for Zika virus diagnostics and vaccines is explored.

Our 78-page report provides 28 tables, charts, and graphs. Understand the virus and the future of the current outbreak. Our new study lets you assess the impact the virus might have on a number of regions, and the complications that have so far been associated with it.

Forecasts from 2016-2026 and other analyses show you commercial prospects

This report provides forecasts for both the infectious disease diagnostics market and the human vaccines market to 2026, and discussed the possible future contributors to these markets in relation to the Zika virus. Discover the symptoms, transmission, history and economic and social impacts of this virus.

See revenue forecasts for the associated markets

How will associated markets perform to 2026? Our study forecasts revenues in the following related markets:

  • Infectious Disease Diagnostics Market
  • Global Vaccines Market

Leading Vaccine Manufacturers and Companies Searching for a Zika Virus Vaccine

The number of patients infected with the Zika virus is predicted to soar, and the need for a vaccine is becoming ever more apparent. We discuss some of the leading international vaccine manufacturing companies, and then take a look at the companies that are currently developing vaccines or the Zika virus.

Companies included in this report include:

  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi
  • Bharat Biotech
  • Inovio Pharmaceuticals

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What does the Zika virus outbreak mean for the future?

Our new report discusses issues and events regarding the Zika virus outbreak, currently in Central and South America. You will find discussions, including analysis of past outbreaks, the virus' modes of transmission, symptoms. Future trends include:

  • Increasing economic and social pressures related to the virus
  • Development of a vaccine will lead to large financial returns
  • The virus is likely to spread from its current territories, to include the US and possibly much of Southern Europe, Africa and Asia.

How the Zika Virus Report report helps you

In summary, our 78-page report gives you the following knowledge:

  • Understanding of the structure, replication mechanisms and transmission modes of the Zika virus
  • An in-depth history of previous Zika virus outbreaks and detail the viruses spread from Africa
  • Study of the potential spread of the virus, looking at the areas in which the virus' vectors are able to survive on a global scale
  • Intelligence on important markets that will be affected by the Zika virus outbreak
  • Revenue forecast for the Infectious Disease Diagnostics Market covering the period 2016 to 2026
  • Revenue forecast for the Global Vaccines Market covering the period 2016 to 2026.
  • Profiles of leading companies operating within the vaccines market
  • Significant social and economic issues arising from the spread of the Zika virus
  • Conclusions and recommendations

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the cholesterol-lowering drugs market and leading companies. You will find data, trends and predictions. Please order our report now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of Findings
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered By This Analytical Report
  • 1.5. Who Is This Report For?
  • 1.6. Structure of the Report
  • 1.7. Research and Analysis Methods
  • 1.8. Exchange Rates
  • 1.9. Frequently Asked Questions
  • 1.10. Associated Visiongain Reports
  • 1.11. About Visiongain

2. Introduction to Zika Virus

  • 2.1. The Zika Virus
    • 2.1.1. Flavivirus Structure
    • 2.1.2. Zika Virus Replication Mechanism
    • 2.1.3. Modes of Transmission
  • 2.2. Outline of Previous Zika Outbreaks
  • 2.3. Symptoms of ZIVD
    • 2.3.1. Microcephaly

3. Zika Outbreak 2015/2016

  • 3.1. The Progression of Zika in the Americas
  • 3.2. Areas at Risk from Zika Infection
    • 3.2.1. Areas with Ae.aegypti Populations
    • 3.2.2. Areas with Ae.albopictus Populations
  • 3.3. Containment Measures
    • 3.3.1. Efforts in Affected Countries
    • 3.3.2. Efforts in Un-Affected Countries
  • 3.4. Basic Reproductive Number
    • 3.4.1. Related Virus Basic Reproduction Numbers

4. Diagnostic Tools for the Detection of Zika Virus

  • 4.1. The Infectious Disease Diagnostics Market
  • 4.2. Infectious Disease Diagnostics Market Forecast, 2016-2026
  • 4.3. Diagnosis of Zika Infection
    • 4.3.1. Laboratory Tests for the Diagnosis of Zika Virus Disease
    • 4.3.2. Commercial and Point-of-Care Tests
      • 4.3.2.1. Biocan Diagnostics

5. Zika Virus Vaccine: Pipeline Candidates

  • 5.1. Global Vaccine Market, 2014
  • 5.2. Global Vaccine Market Forecast, 2016-2026
  • 5.3. Leading Manufacturers of Human Vaccines
    • 5.3.1. GlaxoSmithKline (GSK)
    • 5.3.2. Merck & Co (MSD)
    • 5.3.3. Sanofi
    • 5.3.4. Pfizer
  • 5.4. No Zika Virus Vaccine Currently Available
  • 5.5. Zika Virus Vaccine Pipeline
    • 5.5.1. Bharat Biotech
    • 5.5.2. Sanofi Pasteur
    • 5.5.3. Inovio Pharmaceuticals
    • 5.5.4. Other Companies

6. Economic and Socio-Economic Effects of the Zika Virus Outbreak

  • 6.1. Overview of Impact on Affected Nations
  • 6.2. Zika Virus and Pregnancy in Affected Countries
  • 6.3. Tourism and Major Events
    • 6.3.1. Comparison with Other Viral Epidemics - Ebola Outbreak 2014
  • 6.4. Healthcare Services and Support
  • 6.5. Predicted Impact of Further Spread

7. Glossary

List of Tables

  • Table 1.1: Currency Exchange Rates, 2015
  • Table 2.1: Modes of Infection of the Zika Virus and Their Confirmation Status
  • Table 2.2: Number of Live Births (000's) For a Selection of Countries in the Affected Region, 2011
  • Table 3.1: Countries/Territories with Active Zika Transmission as of 11th February 2016
  • Table 4.1: The Infectious Disease Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 5.1: The Global Vaccines Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 6.1: Countries at Risk of Infection and Number of Tourists (millions), 2013
  • Table 6.2: Number of Live Births in US States at High and Low Risk of Active Zika Transmission, and the Percentage of Live Births of Each (%)
  • Table 6.3: Number of Live Births in US States at High Risk of Active Zika Transmission, 2014

List of Figures

  • Figure 2.1: Representation of the Structure of a Flavivirus
  • Figure 2.2: Representation of the Genome of a Flavivirus
  • Figure 2.3: The Federated States of Micronesia, Location of 2007 Zika Virus Outbreak, with Yap Island Highlighted
  • Figure 2.4: Map of Pacific Islands, with Area of French Polynesia Highlighted
  • Figure 2.5: A Comparison of the Head Size of an Infant with Microcephaly and Without
  • Figure 2.6: Cases of Suspected Microcephaly in Brazil from 2011 to 2016
  • Figure 3.1: Location of Camaçari, Brazil, First Location to Report Zika Virus in the Americas
  • Figure 3.2: Population Density Map of Brazil, with Major Cities Labelled
  • Figure 3.3: Areas Showing Zika Virus Transmission, December 2015 and January 2016, excluding Pacific Islands
  • Figure 3.4: Likelihood of Occurrence of Ae.aegypti across the Americas
  • Figure 3.5: Likelihood of Occurrence of Ae.aegypti across Europe and Africa
  • Figure 3.6: Likelihood of Occurrence of Ae. Aegypti across the Asia-Pacific
  • Figure 3.7: Likelihood of Occurrence of Ae.albopictus across the Americas
  • Figure 3.8: Likelihood of Occurrence of Ae.albopictus across Europe and Africa
  • Figure 3.9: Likelihood of Occurrence of Ae.albopictus across the Asia-Pacific
  • Figure 4.1: The Infectious Disease Testing Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 4.2: Pan American Health Organization Zika Diagnosis Advice, 2015
  • Figure 5.1: The Global Vaccines Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
  • Figure 6.1: Percentage of Live US Births That Occurred in States with a High Risk and Low Risk of Active Zika Transmission, 2014

Companies Listed

  • Baxter
  • Bharat Biotech
  • CSL
  • GeneOne Life Sciences
  • GlaxoSmithKline
  • GlaxoWellcome
  • Inovio Pharmaceuticals
  • Merck
  • Novarits
  • Pfizer
  • Regulus Therapeutics
  • Sanofi
  • SmithKline Beecham
  • Takeda Pharmaceuticals

List of Organisations

  • Centre for Disease Control
  • European Centre for Disease Prevention and Control
  • Fédération Internationale de Football Association (FIFA)
  • Pan American Health Organisation
  • The Catholic Church
  • World Health Organisation
Back to Top